Finch Therapeutics Group (NASDAQ:FNCH – Get Rating) is one of 255 publicly-traded companies in the “Biological products, except diagnostic” industry, but how does it contrast to its peers? We will compare Finch Therapeutics Group to similar companies based on the strength of its institutional ownership, profitability, earnings, analyst recommendations, risk, valuation and dividends.
This is a summary of recent recommendations for Finch Therapeutics Group and its peers, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Finch Therapeutics Group||0||0||1||0||3.00|
|Finch Therapeutics Group Competitors||1634||5698||11345||209||2.54|
This table compares Finch Therapeutics Group and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Finch Therapeutics Group||-313.84%||-26.15%||-23.87%|
|Finch Therapeutics Group Competitors||-3,792.11%||-66.41%||-29.84%|
Valuation and Earnings
This table compares Finch Therapeutics Group and its peers revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Finch Therapeutics Group||$18.53 million||-$58.16 million||-1.10|
|Finch Therapeutics Group Competitors||$773.46 million||$147.16 million||-0.08|
Finch Therapeutics Group’s peers have higher revenue and earnings than Finch Therapeutics Group. Finch Therapeutics Group is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Risk and Volatility
Finch Therapeutics Group has a beta of 0.89, indicating that its stock price is 11% less volatile than the S&P 500. Comparatively, Finch Therapeutics Group’s peers have a beta of 0.76, indicating that their average stock price is 24% less volatile than the S&P 500.
Insider and Institutional Ownership
22.7% of Finch Therapeutics Group shares are owned by institutional investors. Comparatively, 53.2% of shares of all “Biological products, except diagnostic” companies are owned by institutional investors. 16.0% of shares of all “Biological products, except diagnostic” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Finch Therapeutics Group beats its peers on 7 of the 13 factors compared.
Finch Therapeutics Group Company Profile (Get Rating)
Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company's lead candidate is CP101, an orally administered microbiome capsule that is in Phase 3 clinical trial for the treatment of patients with recurrent Clostridioides difficile infection, as well as for the treatment of chronic hepatitis B virus. It is also developing FIN-211, an orally administered enriched consortia product candidate for use in the treatment of autism spectrum disorder; and TAK-524 and FIN-525, which are orally administered targeted consortia product candidates for the treatment of ulcerative colitis and Crohn's disease. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; Skysong Innovations LLC; and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Somerville, Massachusetts.
Receive News & Ratings for Finch Therapeutics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Finch Therapeutics Group and related companies with MarketBeat.com's FREE daily email newsletter.